Upcoming Dividend • Jun 02
Upcoming dividend of HK$0.40 per share Eligible shareholders must have bought the stock before 09 June 2026. Payment date: 22 June 2026. Payout ratio is a comfortable 52% but the company is paying out more than the cash it is generating. Trailing yield: 5.6%. Lower than top quartile of Hong Kong dividend payers (6.9%). Higher than average of industry peers (2.8%). Announcement • May 26
Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2025 Consun Pharmaceutical Group Limited at its Annual General Meeting held on May 26, 2026, approved To declare and pay to the shareholders of the Company a final dividend of HKD 0.40 per ordinary share of the Company for the year ended 31 December 2025. Declared Dividend • Mar 28
Final dividend of HK$0.40 announced Shareholders will receive a dividend of HK$0.40. Ex-date: 9th June 2026 Payment date: 22nd June 2026 Dividend yield will be 4.2%, which is higher than the industry average of 3.6%. Sustainability & Growth Dividend is well covered by both earnings (36% earnings payout ratio) and cash flows (42% cash payout ratio). The dividend has increased by an average of 26% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 42% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Mar 27
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: CN¥1.27 (up from CN¥1.11 in FY 2024). Revenue: CN¥3.42b (up 15% from FY 2024). Net income: CN¥1.08b (up 18% from FY 2024). Profit margin: 32% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.8%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Mar 26
Consun Pharmaceutical Group Limited, Annual General Meeting, May 26, 2026 Consun Pharmaceutical Group Limited, Annual General Meeting, May 26, 2026. Announcement • Mar 05
Consun Pharmaceutical Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026 Consun Pharmaceutical Group Limited announced that they will report fiscal year 2025 results on Mar 26, 2026 Reported Earnings • Sep 24
First half 2025 earnings released: EPS: CN¥0.59 (vs CN¥0.50 in 1H 2024) First half 2025 results: EPS: CN¥0.59 (up from CN¥0.50 in 1H 2024). Revenue: CN¥1.57b (up 24% from 1H 2024). Net income: CN¥498.3m (up 25% from 1H 2024). Profit margin: 32% (in line with 1H 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 73% per year, which means it is tracking significantly ahead of earnings growth. Declared Dividend • Aug 21
First half dividend of HK$0.33 announced Shareholders will receive a dividend of HK$0.33. Ex-date: 4th September 2025 Payment date: 19th September 2025 Dividend yield will be 4.5%, which is higher than the industry average of 3.6%. Sustainability & Growth Dividend is covered by both earnings (49% earnings payout ratio) and cash flows (51% cash payout ratio). The dividend has increased by an average of 23% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Aug 20
First half 2025 earnings released: EPS: CN¥0.59 (vs CN¥0.50 in 1H 2024) First half 2025 results: EPS: CN¥0.59 (up from CN¥0.50 in 1H 2024). Revenue: CN¥1.57b (up 24% from 1H 2024). Net income: CN¥498.3m (up 25% from 1H 2024). Profit margin: 32% (in line with 1H 2024). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 19
Consun Pharmaceutical Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2025 , Payable on September 19, 2025 Consun Pharmaceutical Group Limited announced Interim Dividend of HKD 0.33 per share for the six months ended 30 June 2025. Ex-dividend date: 04 September 2025, Record date: 05 September 2025. Payment date: 19 September 2025. Announcement • Aug 06
Consun Pharmaceutical Group Limited to Report First Half, 2025 Results on Aug 19, 2025 Consun Pharmaceutical Group Limited announced that they will report first half, 2025 results on Aug 19, 2025 Recent Insider Transactions • Jul 15
CEO & Executive Chairman recently bought HK$2.9m worth of stock On the 11th of July, Meng An bought around 251k shares on-market at roughly HK$11.36 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Meng has been a buyer over the last 12 months, purchasing a net total of HK$41m worth in shares. Announcement • Jun 20
Consun Pharmaceutical Group Limited Announces Nomination Committee Changes, Effective from 20 June 2025 Consun Pharmaceutical Group Limited announced the following changes in the composition of the nomination committee of the Board (the "Nomination Committee") with effect from 20 June 2025. Mr. An Meng, the chairman of the Board and an executive Director, has ceased to be a member of the Nomination Committee; and Dr. Zhang Lihua, a non-executive Director, has been appointed as a member of the Nomination Committee. Following the above changes, the Nomination Committee will comprise three members, namely Professor Li Yikai (chairman), Dr. Zhang Lihua, and Mr. Duan Weiwu. Upcoming Dividend • Jun 03
Upcoming dividend of HK$0.30 per share Eligible shareholders must have bought the stock before 10 June 2025. Payment date: 20 June 2025. Payout ratio is a comfortable 51% and this is well supported by cash flows. Trailing yield: 5.4%. Lower than top quartile of Hong Kong dividend payers (7.7%). Higher than average of industry peers (2.5%). Announcement • May 22
Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2024 Consun Pharmaceutical Group Limited announced that at the AGM held on May 22, 2025 approved to pay to the shareholders of the Company a final dividend of HKD 0.3 per ordinary share of the Company for the year ended 31 December 2024. Reported Earnings • May 03
Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat Full year 2024 results: EPS: CN¥1.11 (up from CN¥0.99 in FY 2023). Revenue: CN¥2.97b (up 15% from FY 2023). Net income: CN¥910.5m (up 16% from FY 2023). Profit margin: 31% (in line with FY 2023). Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to HK$9.76, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 9x in the Pharmaceuticals industry in Hong Kong. Total returns to shareholders of 198% over the past three years. Board Change • Apr 10
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-executive Director Zhuoguang Li was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Apr 08
Consun Pharmaceutical Group Limited Announces Executive and Committee Changes Consun Pharmaceutical Group Limited announced that with effect from 8 April 2025, Mr. Young Yuk Chuen David ("Mr. Young") has been appointed as an executive Director, the overseas business director and a member of the environmental, social and governance committee (the "ESG Committee"); and Mr. Duan Weiwu (" Mr. Duan ") has been appointed as an independent non-executive Director, and a member of the audit committee (the "Audit Committee") and the nomination. Mr. Young Yuk Chuen David, aged 27, has obtained his bachelor's degree of science,in operations management and management and leadership from Boston College in May 2020 and his master's degree in management from Institut Européen d'Administration des Affaires (INSEAD) in June 2022. He also holds certificates of PMI Disciplined Agile Scrum Master, ASQ Six Sigma Yellow Belt, CAIA Fundamentals of Alternative Investments & Private Debt, Series 65. Mr. Young will be responsible for the participation in the introduction of the Group's international investment projects and development for overseas business. Mr. Young has extensive experience in researching international macro and fundamental investment strategies. He has been serving as the managing director of Champ Standard, an investment management firm, since July 2023. Mr. Young is the son of Mr. Young Wai Po, Peter, a substantial shareholder of the Company, who owns all issued shares of Guidoz Limited, which in turn owns 110,050,000 shares of the Company (representing approximately 12.94% of the total issued shares of the Company as at the date of this announcement).Mr. Duan Weiwu aged 49, is a lawyer qualified in the PRC and has over 20 years of experience in the provision of commercial legal services. He has been a partner of Dacheng
Guangzhou office of Beijing Dacheng Law Offices, LLP since October 2019. From October 2006 to October 2019, Mr. Duan served as a lawyer and has been promoted to senior partner at Guangdong Jinglun Law Firm in 2016.
Mr. Duan obtained his bachelor's degree in law from Zhongnan Institute of Law (now known as Zhongnan University of Economics and Law in 1999 with and his master's degree in law from Sun Yat-sen University in 2007. He is also an arbitrator of Guangzhou Arbitration Commission and Wuhan Arbitration Commission. Mr. Duan has extensive experience in the fields of pharmaceutical commerce, pharmaceutical research and development, and legal services for pharmaceutical commercial transactions. He has been selected as a "Recommended Lawyer" in the field of life sciences and healthcare legal services in the legal market in Greater China for 2025 published by The Legal 500, an international authoritative legal rating agency. The Board further announces that with effect from 8 April 2025, (i) Mr. Feng Zhongshi, an independent non-executive Director, ceased to be a member of the Audit Committee; and (ii) Mr. Li Zhuoguang, an independent non-executive Director, ceased to be a member of the Nomination Committee and the ESG Committee. Declared Dividend • Mar 28
Final dividend of HK$0.30 announced Shareholders will receive a dividend of HK$0.30. Ex-date: 10th June 2025 Payment date: 20th June 2025 Dividend yield will be 6.7%, which is higher than the industry average of 3.6%. Sustainability & Growth Dividend is covered by both earnings (51% earnings payout ratio) and cash flows (56% cash payout ratio). The dividend has increased by an average of 22% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 48% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Mar 27
Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat Full year 2024 results: EPS: CN¥1.11 (up from CN¥0.99 in FY 2023). Revenue: CN¥2.97b (up 15% from FY 2023). Net income: CN¥910.5m (up 16% from FY 2023). Profit margin: 31% (in line with FY 2023). Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Mar 13
Consun Pharmaceutical Group Limited Announces First Cohort of Subjects Dosed for A Phase 1 Clinical Trial of SK-08 Tablet Consun Pharmaceutical Group Limited announced that the Group is conducting a Phase 1 trial for evaluating the safety, tolerability and pharmacokinetic of SK-08 Tablet. The first cohort of subjects has been successfully dosed. Chronic kidney disease ("CKD") represents a significant global public health challenge, posing severe risks to human health. In the PRC, the number of affected individuals has exceeded 100 million, with the incidence rate showing a consistent upward trend year by year. Patients with CKD experience a progressive decline in renal function, which may ultimately progress to end-stage renal disease (ESRD), necessitating dialysis or kidney transplantation. This imposes substantial physical, emotional, and financial burdens on patients and their families. SK-08 Tablet is a Category 1 innovative drug with global intellectual property rights jointly developed by the Group and another pharmaceutical company. Its unique mechanism of action precisely targets soluble guanylate cyclase (sGC), which is independent of the presence of nitric oxide, and promotes the generation of cGMP, which in turn can help reduce proteinuria and safeguard the functions of the kidney through multiple biological effects such as vasodilation, increasing kidney blood supply, improving glomerular filtration rate, anti-inflammation and anti-fibrosis. Additionally, it regulates reabsorption in the kidney, enhances cardiac function and mitigates the risks of thrombosis. In preclinical trials, SK-08 Tablet significantly reduced proteinuria, improved kidney functions and alleviated glomerulosclerosis, and was well tolerated with good safety profile. Currently, there is no other drug adopting similar mechanism approved for the treatment of CKD across the world. SK-08 Tablet is expected to fill this gap and will provide a new treatment option for patients with CKD. The Group envisages to promote prioritization of kidney health, early screening and prevention, and actively explore innovative treatment solutions, and the successful dosing of the first cohort of subjects marks another significant milestone for the Group in the development of innovative therapeutics for kidney disease. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. Announcement • Mar 05
Consun Pharmaceutical Group Limited to Report Fiscal Year 2024 Results on Mar 26, 2025 Consun Pharmaceutical Group Limited announced that they will report fiscal year 2024 results on Mar 26, 2025 Announcement • Feb 25
Consun Pharmaceutical Group Limited Announces CFO Changes The board of directors of Consun Pharmaceutical Group Limited announced that with effect from 24 February 2025, Mr. Fang Peicheng, formerly the vice president and chief financial officer of the Group, ceased to concurrently serve as Chief Financial Officer and continued to hold the position of vice president of the Group. Ms. Chen has been appointed as the Chief Financial Officer with effect from 24 February 2025. Ms. Chen Yujun served as an independent non-executive Director and among others, acted as the chairlady of the Audit Committee with appropriate professional qualifications and accounting expertise, from 31 May 2019 to immediately prior to the Resignation. Announcement • Feb 24
Consun Pharmaceutical Group Limited Announces Board and Committee Changes The board of directors of Consun Pharmaceutical Group Limited announced that with effect from 24 February 2025: Ms. Chen Yujun has resigned as an independent non-executive Director, and ceased to be the chairlady of the audit committee, and a member of the nomination committee, the remuneration committee and the environmental, social and governance committee and Mr. Li Zhuoguang has been appointed as an independent non-executive Director, the chairman of the Audit Committee, and a member of the Nomination Committee, the Remuneration Committee and the ESG Committee in place of Ms. Chen. The Resignation took effect from 24 February 2025, due to the reallocation of responsibilities in the Group's management. The Appointment took effect from 24 February 2025. Mr. Li, aged 42, has around 20 years of experience in audit and accounting works in the PRC. Mr. Li has been working for GUANGZHOU HEYGEARS IMC. INCas an executive director and assistant to the chairman of the board since August 2023. From January 2013 to June 2023, Mr. Li worked for Jiumaojiu International Holdings Limited,a company whose shares are listed on the Stock Exchange (stock code: 9922), and his last position was executive director and chief financial officer of Jiumaojiu and vice president of Guangzhou Jiumaojiu Catering Chain Co. Ltd. He worked at Tianji Real Estate Development (Shenzhen) Co., Lt, a real property development company as vice financial controller from April to December 2012 and KPMG Huazhen LLP as manager dfrom June 2005 to April 2012. Mr. Li became a member of the Chinese Institute of Certified Public Accountants in August 2008. He graduated from Sun Yat-sen University in July 2005 with a bachelor's degree in English. Reported Earnings • Oct 01
First half 2024 earnings released: EPS: CN¥0.50 (vs CN¥0.44 in 1H 2023) First half 2024 results: EPS: CN¥0.50 (up from CN¥0.44 in 1H 2023). Revenue: CN¥1.27b (up 13% from 1H 2023). Net income: CN¥399.8m (up 15% from 1H 2023). Profit margin: 32% (in line with 1H 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to HK$7.11, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 9x in the Pharmaceuticals industry in Hong Kong. Total returns to shareholders of 165% over the past three years. Recent Insider Transactions • Sep 04
CEO & Executive Chairman recently bought HK$5.4m worth of stock On the 2nd of September, Meng An bought around 950k shares on-market at roughly HK$5.64 per share. This transaction amounted to 5.8% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$7.7m. Meng has been a buyer over the last 12 months, purchasing a net total of HK$16m worth in shares. Declared Dividend • Aug 23
First half dividend of HK$0.30 announced Shareholders will receive a dividend of HK$0.30. Ex-date: 5th September 2024 Payment date: 20th September 2024 Dividend yield will be 16%, which is higher than the industry average of 3.6%. Sustainability & Growth Dividend is covered by both earnings (39% earnings payout ratio) and cash flows (59% cash payout ratio). The dividend has increased by an average of 22% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 53% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Aug 22
Consun Pharmaceutical Group Limited Announces Executive Changes Consun Pharmaceutical Group Limited announced that Mr. Yau Chi Ming has resigned as the company secretary of the Company and ceased to act as an authorised representative of the Company. the Board Further Announces That Following Mr. Yau's Resignation, Mr. Gao Haien has been appointed as the Company Secretary and the Authorised Representative with Effect from 22 August 2024. Mr. Gao, Aged 55, Has Been the Board Secretary of Guangzhou Consun Pharmaceutical Company Limited Since August 2007 and the Board Secretary Since the Listing of the Company on the Stock Exchange on 19 December 2013. Mr. Gao Has Been the Manager and Legal Representative of Guangzhou Consun and Consun Pharmaceutical (Inner Mongolia) Co. Ltd. Since March 2013, the Manager and Legal Representative of Guangxi Yulin Pharmaceutical Group Co. Ltd. and Guangzhou Consun Medicine Co. Ltd. Since August 2015, A Director of Yulin Pharmaceutical and Inner Mongolia Consun Since August 2018, and A Director and Legal Representative of Consun Pharmaceutical (Horgos) Co. Ltd. Since December 2020. Mr. Gao Also Acted as the Joint Company Secretary of the Company (The "Joint Company Secretary") from 15 April 2014 to 31 May 2017. Prior to Joining Our Group, Mr. Gao Served as A General Manager of the Accessories Store and the Assistant to Headquarters General Manager of Shenzhen Sunyes Tools Co. Ltd. from January 2006 to August 2007. Between July 1995 and January 2006, Mr. Gao Served as A Senior Engineer of Idt Data System Factory and A Technology Manager of Shenzhen Aomeidi Digital Technology Co. Ltd. Mr. Gao Graduated from China University of Mining and Technology in July 1992 with A Bachelor Degree in Engineering and Subsequently Obtained A Bachelor Degree in Economics At the Same University in January 1994. He Obtained A Master's Degree in Business Administration At Zhongnan University of Economics and Law in June 2012. Mr. Gao Holds Professional Certificate in Securities Granted by Securities Association of China and Board Secretary Certificate Granted by the Shenzhen Stock Exchange. Announcement • Aug 21
Consun Pharmaceutical Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 September 2024 Consun Pharmaceutical Group Limited announced the interim dividend of HKD 0.3 per share for the six months ended 30 June 2024. Ex-dividend date is on 05 September 2024 with Record date is on 6 September 2024. Payment date is on 20 September 2024. Announcement • Aug 05
Consun Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024 Consun Pharmaceutical Group Limited announced that they will report first half, 2024 results on Aug 21, 2024 Recent Insider Transactions • Jul 09
CEO & Executive Chairman recently bought HK$7.7m worth of stock On the 5th of July, Meng An bought around 1m shares on-market at roughly HK$5.90 per share. This transaction amounted to 8.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Meng has been a buyer over the last 12 months, purchasing a net total of HK$8.6m worth in shares. Announcement • Jun 21
Consun Pharmaceutical Group Limited Announces Board and Committee Changes The board of directors of Consun Pharmaceutical Group Limited announced that Professor Li Yikai is appointed as an independent non-executive Director, the chairman of the nomination committee and a member of the audit committee of the Company with effect from 21 June 2024. Professor Li, aged 61, has extensive experience in traditional Chinese medicine. He has been a director of teaching and research office of the School of Traditional Chinese Medicine of Southern Medical University since 2004, adjunct professor of The University of Hong Kong and The Chinese University of Hong Kong since September 2000 and September 2022 respectively, vice president of the Journal of Cervicodynia and Lumbodynia since November 2008. Professor Li was also appointed as vice chairman of the National Soft Tissue Pain Research Association from September 2002 to September 2012, vice president of acupotomy branch of China Association of Chinese Medicine from October 2010 to October 2018 and vice president of massage branch of the China Association of Chinese Medicine from December 2010 to December 2018. Professor Li obtained a doctorate degree in medicine from Shanghai University of Traditional Chinese Medicine in July 1995 and became a postdoctoral fellow of Southern Medical University (formerly known as First Military Medical University of the People's Liberation Army in November 1997. He was elected as the first Qihuang Scholars in December 2019, the seventh National traditional Chinese medicine expert instructors and second graded professor in November 2021 respectively. Professor Li won the second prize of China Medical Science and Technology Award in March 2023 and first prize of National Teaching Achievements in July 2023. CHANGES IN COMPOSITION OF BOARD COMMITTEES: With effect from 21 June 2024: (i) Dr. Zhang Lihua has ceased to be a member of the Audit Committee and Professor Li has been appointed as a member of the Audit Committee. (ii) Mr. Feng Zhongshi has ceased to be the chairman and a member of the Nomination Committee and Professor Li has been appointed as the chairman and a member of the Nomination Committee. Recent Insider Transactions • Jun 15
Chief Scientist & Executive Director recently sold HK$8.4m worth of stock On the 6th of June, Quan Zhu sold around 1m shares on-market at roughly HK$6.56 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth HK$62m. Insiders have been net sellers, collectively disposing of HK$70m more than they bought in the last 12 months. New Risk • Jun 05
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (4.2% increase in shares outstanding). Significant insider selling over the past 3 months (HK$62m sold). Announcement • May 31
Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023 Consun Pharmaceutical Group Limited announced that at the AGM held on May 31, 2024 approved to pay to the shareholders of the Company a final dividend of HKD 0.3 per ordinary share of the Company for the year ended 31 December 2023. Recent Insider Transactions • May 29
Insider recently sold HK$62m worth of stock On the 21st of May, Yubao An sold around 9m shares on-market at roughly HK$6.70 per share. This transaction amounted to 4.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Announcement • May 25
Consun Pharmaceutical Group Limited Announces Special Dividend, Payable on 21 June 2024 Consun Pharmaceutical Group Limited announced special dividend of HKD 0.3 per share. Ex-dividend date is 11 June 2024. Record date is 12 June 2024. Payment date is 21 June 2024. Reported Earnings • May 02
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: EPS: CN¥0.99 (up from CN¥0.86 in FY 2022). Revenue: CN¥2.59b (up 11% from FY 2022). Net income: CN¥784.5m (up 15% from FY 2022). Profit margin: 30% (up from 29% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.0%. Earnings per share (EPS) exceeded analyst estimates by 5.4%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Announcement • Mar 29
Consun Pharmaceutical Group Limited, Annual General Meeting, May 31, 2024 Consun Pharmaceutical Group Limited, Annual General Meeting, May 31, 2024. Reported Earnings • Mar 29
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: EPS: CN¥0.99 (up from CN¥0.86 in FY 2022). Revenue: CN¥2.59b (up 11% from FY 2022). Net income: CN¥784.5m (up 15% from FY 2022). Profit margin: 30% (up from 29% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.0%. Earnings per share (EPS) exceeded analyst estimates by 5.4%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 12% per year. Announcement • Mar 28
Consun Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 21 June 2024 Consun Pharmaceutical Group Limited proposed final dividend for the year ended 31 December 2023 of HKD 0.3 per share. The dividend will be payable on 21 June 2024 with Record date of 12 June 2024 and Ex-dividend date of 11 June 2024. Date of shareholders' approval on 31 May 2024. Announcement • Mar 08
Consun Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 Consun Pharmaceutical Group Limited announced that they will report fiscal year 2023 results on Mar 28, 2024 Announcement • Jan 19
Consun Pharmaceutical Group Limited Announces Management Changes The board of directors of Consun Pharmaceutical Group Limited announced that Ms. LI Qian (Ms. Li) has resigned from the position of an executive Director of the Company, vice chairlady of the Board, the chief executive officer, a member of the remuneration committee of the Company (the Remuneration Committee) and all other positions with the Group with effect from 17 January 2024, due to health reasons. Ms. Li has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited or the shareholders of the Company. The Company announces that Mr. An Meng, the Chairman of the Board and an executive Director, has been appointed as the chief executive officer with effect from 17 January 2024. Pursuant to code provision C.2.1 of the Corporate Governance Code in Appendix 14 to the Rules Governing the Listing of Securities on the Stock Exchange (the Listing Rules), the roles of chairman and the chief executive officer should be separate and should not be performed by the same individual. Despite the deviation from C.2.1 of the code provision of the Listing Rules for Mr. An Meng serves as the Chairman of the Board as well as the chief executive officer of the Company, the Board believes that Mr. An Meng being the Chairman of the Board, is familiar with the Company's business operation and has excellent knowledge and experience of the Company's business which will be conducive to improving the efficiency of the Company's overall strategic planning. The Board believes that such management structure layout will be more beneficial to the future development of the Company and will improve the Company's operating conditions. Under the supervision of the Board which will comprise of three executive Directors, one non-executive Director and three independent non-executive Directors, the Board is appropriately structured with balance of power to provide sufficient checks to protect the interests of the Company and its shareholders. With effect from 17 January 2024 and following the resignation of Ms. Li, Mr. An Meng has been appointed to be a member of the Remuneration Committee in place of Ms. Li. Reported Earnings • Sep 29
First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.37 in 1H 2022) First half 2023 results: EPS: CN¥0.44 (up from CN¥0.37 in 1H 2022). Revenue: CN¥1.12b (up 13% from 1H 2022). Net income: CN¥347.9m (up 17% from 1H 2022). Profit margin: 31% (up from 30% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Aug 31
Upcoming dividend of HK$0.15 per share at 6.2% yield Eligible shareholders must have bought the stock before 07 September 2023. Payment date: 20 September 2023. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 6.2%. Lower than top quartile of Hong Kong dividend payers (7.7%). Higher than average of industry peers (3.5%). Reported Earnings • Aug 25
First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.37 in 1H 2022) First half 2023 results: EPS: CN¥0.44 (up from CN¥0.37 in 1H 2022). Revenue: CN¥1.12b (up 13% from 1H 2022). Net income: CN¥347.9m (up 17% from 1H 2022). Profit margin: 31% (up from 30% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Announcement • Aug 25
Consun Pharmaceutical Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 20 September 2023 Consun Pharmaceutical Group Limited announced the interim dividend of HKD 0.15 per share for the six months ended 30 June 2023. Ex-dividend date is on 07 September 2023 with Record date is on 08 September 2023. Payment date is on 20 September 2023. Announcement • Aug 05
Consun Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 24, 2023 Consun Pharmaceutical Group Limited announced that they will report first half, 2023 results on Aug 24, 2023 Announcement • Jun 01
Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2022 Consun Pharmaceutical Group Limited at its annual general meeting held on May 31, 2023, approved to declare and pay to the Shareholders a final dividend of HKD 0.3 per ordinary Share for the year ended 31 December 2022. Upcoming Dividend • Jun 01
Upcoming dividend of HK$0.30 per share at 6.0% yield Eligible shareholders must have bought the stock before 08 June 2023. Payment date: 21 June 2023. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 6.0%. Lower than top quartile of Hong Kong dividend payers (7.9%). Higher than average of industry peers (2.9%). Reported Earnings • May 03
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: CN¥0.86 (up from CN¥0.74 in FY 2021). Revenue: CN¥2.34b (up 14% from FY 2021). Net income: CN¥682.9m (up 16% from FY 2021). Profit margin: 29% (in line with FY 2021). Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) also surpassed analyst estimates by 8.9%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 24
Full year 2022 earnings: Revenues exceed analyst expectations Full year 2022 results: Revenue: CN¥2.34b (up 14% from FY 2021). Net income: CN¥682.9m (up 16% from FY 2021). Profit margin: 29% (in line with FY 2021). Revenue exceeded analyst estimates by 3.2%. Revenue is forecast to grow 9.1% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Hong Kong. Valuation Update With 7 Day Price Move • Dec 05
Investor sentiment improved over the past week After last week's 18% share price gain to HK$3.93, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 10x in the Pharmaceuticals industry in Hong Kong. Total returns to shareholders of 4.7% over the past three years. Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non Executive Director Yujun Chen was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Aug 27
First half 2022 earnings released: EPS: CN¥0.37 (vs CN¥0.31 in 1H 2021) First half 2022 results: EPS: CN¥0.37 (up from CN¥0.31 in 1H 2021). Revenue: CN¥993.5m (up 12% from 1H 2021). Net income: CN¥296.7m (up 18% from 1H 2021). Profit margin: 30% (up from 28% in 1H 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 11%, compared to a 37% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Aug 02
Investor sentiment deteriorated over the past week After last week's 15% share price decline to HK$3.90, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 10x in the Pharmaceuticals industry in Hong Kong. Total returns to shareholders of 5.9% over the past three years. Upcoming Dividend • May 26
Upcoming dividend of HK$0.20 per share Eligible shareholders must have bought the stock before 02 June 2022. Payment date: 17 June 2022. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 6.9%. Lower than top quartile of Hong Kong dividend payers (7.8%). Higher than average of industry peers (2.7%). Reported Earnings • Apr 29
Full year 2021 earnings released: EPS: CN¥0.74 (vs CN¥0.61 in FY 2020) Full year 2021 results: EPS: CN¥0.74 (up from CN¥0.61 in FY 2020). Revenue: CN¥2.04b (up 17% from FY 2020). Net income: CN¥590.2m (up 18% from FY 2020). Profit margin: 29% (in line with FY 2020). Over the next year, revenue is forecast to grow 11%, compared to a 104% growth forecast for the pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non Executive Director Yujun Chen was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment improved over the past week After last week's 21% share price gain to HK$3.85, the stock trades at a trailing P/E ratio of 4.6x. Average trailing P/E is 9x in the Pharmaceuticals industry in Hong Kong. Total loss to shareholders of 17% over the past three years. Upcoming Dividend • Sep 01
Upcoming dividend of HK$0.10 per share Eligible shareholders must have bought the stock before 08 September 2021. Payment date: 23 September 2021. Trailing yield: 8.1%. Within top quartile of Hong Kong dividend payers (6.7%). Higher than average of industry peers (1.9%). Reported Earnings • Aug 26
First half 2021 earnings released: EPS CN¥0.31 (vs CN¥0.25 in 1H 2020) The company reported a solid first half result with improved earnings and revenues, although profit margins were flat. First half 2021 results: Revenue: CN¥886.5m (up 16% from 1H 2020). Net income: CN¥250.6m (up 20% from 1H 2020). Profit margin: 28% (in line with 1H 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Jul 20
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥5.65, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 13x in the Pharmaceuticals industry in Hong Kong. Total returns to shareholders of 2.6% over the past three years. Executive Departure • Jul 16
Chairman of the Board Yubao An has left the company On the 9th of July, Yubao An's tenure as Chairman of the Board ended. As of March 2021, Yubao still personally held 207.13m shares (HK$833m worth at the time). Yubao is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.42 years, which is considered inexperienced in the Simply Wall St Risk Model. Upcoming Dividend • May 22
Upcoming dividend of HK$0.20 per share Eligible shareholders must have bought the stock before 28 May 2021. Payment date: 11 June 2021. Trailing yield: 4.7%. Lower than top quartile of Hong Kong dividend payers (6.0%). Higher than average of industry peers (1.4%). Valuation Update With 7 Day Price Move • May 22
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥5.90, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 13x in the Pharmaceuticals industry in Hong Kong. Total loss to shareholders of 25% over the past three years. Valuation Update With 7 Day Price Move • May 04
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥4.95, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 12x in the Pharmaceuticals industry in Hong Kong. Total loss to shareholders of 37% over the past three years. Reported Earnings • Apr 24
Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.094 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥1.75b (up 1.4% from FY 2019). Net income: CN¥498.8m (up CN¥419.0m from FY 2019). Profit margin: 28% (up from 4.6% in FY 2019). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 24% per year whereas the company’s share price has fallen by 20% per year. Reported Earnings • Mar 24
Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.094 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥1.75b (up 1.4% from FY 2019). Net income: CN¥498.8m (up CN¥419.0m from FY 2019). Profit margin: 28% (up from 4.6% in FY 2019). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 24% per year whereas the company’s share price has fallen by 23% per year. Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥3.95, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 11x in the Pharmaceuticals industry in Hong Kong. Total loss to shareholders of 50% over the past three years. Is New 90 Day High Low • Jan 19
New 90-day high: HK$3.40 The company is up 4.0% from its price of HK$3.26 on 21 October 2020. The Hong Kong market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is HK$16.09 per share. Reported Earnings • Sep 18
First half earnings released Over the last 12 months the company has reported total profits of CN¥39.2m, down 92% from the prior year. Total revenue was CN¥1.55b over the last 12 months, down 19% from the prior year. 
